|
Variable
| |
Patients (%)/median (P25–P75)a
|
Variable
| |
Patients (%)/median (P25–P75)
|
|---|
|
Sex
|
Male
|
290 (83.6)
|
Child class
|
A
|
335 (96.5)
|
| |
Female
|
57 (16.4)
| |
B
|
12 (3.5)
|
|
Age (years)
|
≥ 60
|
95 (27.4)
|
Performance status
|
1
|
144 (41.3)
|
| |
< 60
|
252 (72.6)
| |
0
|
203 (58.2)
|
|
HBsAg
|
Positive
|
300 (86.5)
|
BCLC staging
|
Ad
|
175 (50.4)
|
| |
Negative
|
47 (13.5)
| |
B
|
17 (4.9)
|
|
Liver cirrhosis
|
Yes
|
222 (64)
| |
C
|
155 (44.7)
|
| |
No
|
125 (36)
|
AJCC staging
|
I
|
166 (47.8)
|
|
Portal vein invasion
|
Yes
|
21 (6.1)
| |
II
|
136 (39.2)
|
| |
No
|
326 (93.9)
| |
IIIe
|
45 (13)
|
|
Ascites
|
Yes
|
11 (3.2)
|
CNLC staging
|
I
|
291 (83.9)
|
| |
No
|
336 (96.8)
| |
II
|
33 (9.5)
|
|
Ablation or TACE
|
Yes
|
188 (54.2)
| |
III
|
23 (6.6)
|
| |
No
|
159 (45.8)
|
Neutrophil count
| |
3.6 (2.56–4.72)
|
|
AFP (ng/ml)
|
> 400
|
132 (38)
|
Lymphocyte count
| |
1.45 (1.03–1.84)
|
| |
≤ 400
|
215 (62)
|
Platelet count
| |
150 (109–205)
|
|
Tumor capsule
|
Yes
|
304 (87.6)
|
γ-GT
| |
60 (36–115)
|
| |
No
|
43 (12.4)
|
AST
| |
37 (27–53)
|
|
Tumor number
|
≥ 2
|
42 (12.1)
|
Total bilirubin
| |
15.2 (12–21.2)
|
| |
1
|
305 (87.9)
|
Prothrombin time
| |
11.7 (11–12.4)
|
|
Tumor size (cm)
|
> 5
|
168 (48.4)
|
Albumin
| |
44 (40.7–46.7)
|
| |
≤ 5
|
179 (51.6)
|
Fibrinogen
| |
2.61 (2.13–3.27)
|
|
MVIb
|
Yes
|
172 (49.6)
|
NLR
| |
2.44 (1.71–3.37)
|
| |
No
|
175 (50.4)
|
PLR
| |
104.46(74.69–150.52)
|
|
Cell differentiation
|
Poor
|
35 (10.1)
|
GPR
| |
0.45 (0.22–0.88)
|
| |
Moderate
|
283 (81.6)
|
ALR
| |
26.97 (17.02–44.74)
|
| |
Well
|
29 (8.4)
|
FAR
| |
0.06 (0.05–0.08)
|
|
MKIc
|
Yes
|
33 (9.5)
| | | |
| |
No
|
314 (90.5)
| | | |
- aP25–P75: (lower quartile—upper quartile)
- bMVI: microvascular invasion
- cMKI: multiple kinase inhibitor
- dNine patients with BCLC stage 0 were merged into the BCLC stage A group
- eFive patients with AJCC stage IV were merged into the AJCC stage III group
